NPRA

Directory | Consumers

Increase size

Reset to Default

Decrease size

New Publication: Reaksi Drug Safety News - Issue 4/2017

: Posted By Jauze; 20 July 2017; 12 June 2018; Hits: 14453

User Rating: 1 / 5

REAKSI Drug Safety News,

Issue 4/2017, Vol. 36

Hyoscine Butylbromide Injection: Risk of Serious Adverse Effects in Patients with Underlying Cardiac Disease
Keytruda® (pembrolizumab): Risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Rating:

( 1 Rating )

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

Email: npra@npra.gov.my
Phone: +603-7883 5400
Fax: +603-7956 2924, +603-7956 7075

More Links

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Daily PopUp By YannickTanguy.com

Site Last Modified

Last Modified: Thursday 23 March 2023, 12:08:56.